[go: up one dir, main page]

Gidding et al., 1999 - Google Patents

Vincristine pharmacokinetics after repetitive dosing in children

Gidding et al., 1999

Document ID
6117739872914344157
Author
Gidding C
Meeuwsen-de Boer G
Koopmans P
Uges D
Kamps W
De Graaf S
Publication year
Publication venue
Cancer chemotherapy and pharmacology

External Links

Snippet

Purpose: We studied vincristine disposition after 169 weekly iv bolus injections in 32 children with acute lymphoblastic leukemia, non-Hodgkin lymphoma, or Wilms' tumor. The aim of the study was to determine intrapatient and interpatient variability in vincristine …
Continue reading at link.springer.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Similar Documents

Publication Publication Date Title
Gidding et al. Vincristine pharmacokinetics after repetitive dosing in children
Hebert et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers
Floren et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
Yin et al. Pharmacogenetics and herb–drug interactions: experience with: Ginkgo biloba: and omeprazole
Stone et al. Potential for interactions between caspofungin and nelfinavir or rifampin
Xin et al. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers
Gordi et al. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first‐pass hepatic extraction
Blyden et al. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration
Dowell et al. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin
Egorin et al. A limited sampling strategy for cyclophosphamide pharmacokinetics
Scherer et al. Determination of ciprofloxacin in pharmaceutical formulations using HPLC method with UV detection
Hara et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects
Rolf et al. Time‐dependent interaction between lopinavir/ritonavir and fexofenadine
Frost et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents
Burger et al. The effect of atazanavir and atazanavir/ritonavir on UDP‐glucuronosyltransferase using lamotrigine as a phenotypic probe
Wray et al. Pharmacokinetic drug‐drug interaction with Coadministration of Cannabidiol and Everolimus in a phase 1 healthy volunteer trial
Rouini et al. Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites
Kirby et al. Simultaneous measurement of in vivo P‐glycoprotein and cytochrome P450 3A activities
Kharasch et al. Evaluation of first‐pass cytochrome P4503A (CYP3A) and P‐glycoprotein activities using alfentanil and fexofenadine in combination
Wen et al. Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer
Tsai et al. Regulation of hepatobiliary excretion of sinomenine by P-glycoprotein in Sprague-Dawley rats
Tan et al. Co‐administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction.
Veronese et al. Effect of mibefradil on CYP3A4 in vivo
Lang et al. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin
Bowles et al. Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine